AL East Surgery Cycle: Bassitt Eyes Mid-August, Rodon Stalls, Santander's Recovery Remains Opaque

Chris Bassitt's path back to the Orioles' rotation has crystallized into a concrete window. The right-hander underwent a novel lumbar spine procedure to remove a bone spur in June—a surgery rare enough that Bassitt believes he's the first major league pitcher to have it done—and he's already executing his throwing progression. A long-toss session on Friday and multiple bullpens scheduled for this week signal that his medical team is confident in the repair. Baltimore moved him to the 60-day IL yesterday, establishing August 4 as the earliest possible return date, though mid-August is the more realistic target assuming no complications.

The timing matters for the Orioles' September calculus. Bassitt arrived in Baltimore with a 5.27 ERA across 56⅓ innings, a figure that almost certainly understates his talent—chronic back pain erodes command and hip drive over time, and a healthy version of Bassitt, the two-time All-Star and All-MLB selection, is a different pitcher. Baltimore is riding a seven-game winning streak and sits only two games out of a wild card slot in a congested American League. A functional Bassitt rotation piece by mid-August could be the difference between a meaningless September and contention. That's not speculation; that's the calculus every contender runs.

Carlos Rodon's timeline is hazier. The Yankees left-hander hasn't thrown in game since June 28 due to elbow inflammation. A 10-pitch bullpen session on Friday earned him a PRP injection—standard care for inflammation, not a setback per se, but not a sign of rapid progress either. Manager Aaron Boone said Rodon will attempt a full bullpen before week's end, and the team's initial estimate was 4-to-6 weeks of recovery, which would place his return somewhere in early-to-mid August. But Rodon's track record suggests skepticism is warranted. He's been dinged repeatedly by soft-tissue issues, and elbow inflammation on a left-hander who's logged 160+ innings the past two seasons is a regeneration problem, not a mechanical one. The Yankees' rotation depth—already thin without him—will stay thinned through most of August.

Max Scherzer's situation is even murkier. The Blue Jays veteran received three cortisone injections into his right thumb last Monday, which manager John Schneider framed as a tactical pause rather than a setback. Scherzer has managed only 22 innings at a 10.23 ERA across two separate IL stints this season, and his medical team is now addressing secondary issues—thumb pain that can cascade into delivery mechanics—to ensure a clean return. No timeline has been provided. Anthony Santander, meanwhile, is in month four of a projected five-to-six month recovery window after February labral surgery on his left shoulder, and he's already required a cortisone injection to manage flare-ups. He signed a five-year, $92.5 million free agent deal with Toronto in the 2024-25 offseason and has appeared in zero games this season. The investment is locked in; the timeline is locked out.

For bettors, the takeaway splits across division dynamics and rotation depth. Baltimore's pitching surface gets stronger in the second half if Bassitt returns functional by mid-August—that's an edge for Orioles team totals and moneylines in late August contests when rotation quality matters most. Yankees pitching depth remains a liability through early August; expect their team totals to stay suppressed relative to their offensive ceiling because you're getting a fourth or fifth starter in spots where Rodon should be. Toronto's rotation has Scherzer as a question mark, and their offense has been hamstrung all season by Santander's absence. Look for Blue Jays team totals to remain compressed until Scherzer throws a full game, which hasn't happened yet.